Delta-fly pharma inc.: update on the interim analysis status of phase iii study of dfp-10917 in the patients with r/r aml

Tokushima, japan--(business wire)--following the previous information on jan. 5th. in 2024, we are excited to share our latest development status. the following is the current status of the interim analysis of a phase iii study of dfp-10917 monotherapy in patients with recurrent or refractory acute myeloid leukemia (r/r aml) at multicenter in the us. as there are a long term surviving patients in the 150 patients enrolled in this study, we intend to continue to follow up these patients without.
DAL Ratings Summary
DAL Quant Ranking